Referências

1. Andersson, B., Regulation of body fluids (1977) Annu Rev Physiol., 39, pp. 185-200
2. Verney, E.B., The antidiuretic hormone and the factors which determine its release (1947) Proc R Soc Lond B Biol Sci., 135 (878), pp. 25-106. , Dec 16;
3. Share, L., Role of vasopressin in cardiovascular regulation (1988) Physiol Rev., 68 (4), pp. 1248-1284. , Oct;
4. Shade, R.E., Share, L., Volume control of plasma antidiuretic hormone concentration following acute blood volume expansion in the anesthetized dog (1975) Endocrinology., 97 (4), pp. 1048-1057. , Oct;
5. Johnson, J.A., Zehr, J.E., Moore, W.W., Effects of separate and concurrent osmotic and volume stimuli on plasma ADH in sheep (1970) Am J Physiol., 218 (5), pp. 1273-1280. , May;
6. Ledsome, J.R., Wilson, N., Courneya, C.A., Plasma vasopressin during increases and decreases in blood volume in anaesthetized dogs (1985) Can J Physiol Pharmacol., 63 (3), pp. 224-229. , Mar;
7. Burbach, J.P., Luckman, S.M., Murphy, D., Gainer, H., Gene regulation in the magnocellular hypothalamo-neurohypophysial system (2001) Physiol Rev., 81 (3), pp. 1197-1267. , Jul;
8. Miller, W.L., Molecular genetics of familial central diabetes insipidus (1993) J Clin Endocrinol Metab., 77 (3), pp. 592-595. , Sep;
9. Oliver, G., Schafer, E.A., On the Physiological Action of Extracts of Pituitary Body and certain other Glandular Organs: Preliminary Communication (1895) J Physiol., 18 (3), pp. 277-279. , Jul 18;
10. Turner, R.A., Pierce, J.G., Du, V.V., The purification and the amino acid content of vasopressin preparations (1951) J Biol Chem., 191 (1), pp. 21-28. , Jul;
11. Birnbaumer, M., Seibold, A., Gilbert, S., Ishido, M., Barberis, C., Antaramian, A., Molecular cloning of the receptor for human antidiuretic hormone (1992) Nature., 357 (6376), pp. 333-335. , May 28;
12. Kojro, E., Eich, P., Gimpl, G., Fahrenholz, F., Direct identification of an extracellular agonist binding site in the renal V2 vasopressin receptor (1993) Biochemistry., 32 (49), pp. 13537-13544. , Dec 14;
13. Luzius, H., Jans, D.A., Grunbaum, E.G., Moritz, A., Rascher, W., Fahrenholz, F., A low affinity vasopressin V2-receptor in inherited nephrogenic diabetes insipidus (1992) J Recept Res., 12 (3), pp. 351-368
14. Liu, J., Wess, J., Different single receptor domains determine the distinct G protein coupling profiles of members of the vasopressin receptor family (1996) J Biol Chem., 271 (15), pp. 8772-8778. , Apr 12;
15. Rosenthal, W., Antaramian, A., Gilbert, S., Birnbaumer, M., Nephrogenic diabetes insipidus A V2 vasopressin receptor unable to stimulate adenylyl cyclase (1993) J Biol Chem., 268 (18), pp. 13030-13033. , Jun 25;
16. Knoers, N.V., Molecular characterization of nephrogenic diabetes insipidus (1994) Trends Endocrinol Metab., 5 (10), pp. 422-428. , Dec;
17. Bichet, D.G., Birnbaumer, M., Lonergan, M., Arthus, M.F., Rosenthal, W., Goodyer, P., Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus (1994) Am J Hum Genet., 55 (2), pp. 278-286. , Aug;
18. Fujiwara, T.M., Bichet, D.G., Molecular biology of hereditary diabetes insipidus (2005) J Am Soc Nephrol., 16 (10), pp. 2836-2846. , Oct;
19. Postina, R., Ufer, E., Pfeiffer, R., Knoers, N.V., Fahrenholz, F., Misfolded vasopressin V2 receptors caused by extracellular point mutations entail congential nephrogenic diabetes insipidus (2000) Mol Cell Endocrinol., 164 (1-2), pp. 31-39. , Jun;
20. Carpentier, E., Greenbaum, L.A., Rochdi, D., Abrol, R., Goddard III, W.A., Bichet, D.G., Identification and characterization of an activating F229V substitution in the V2 vasopressin receptor in an infant with NSIAD (2012) J Am Soc Nephrol., 23 (10), pp. 1635-1640. , Oct;
21. Feldman, B.J., Rosenthal, S.M., Vargas, G.A., Fenwick, R.G., Huang, E.A., Matsuda-Abedini, M., Nephrogenic syndrome of inappropriate antidiuresis (2005) N Engl J Med., 352 (18), pp. 1884-1890. , May 5;
22. Rosenthal, S.M., Feldman, B.J., Vargas, G.A., Gitelman, S.E., Nephrogenic syndrome of inappropriate antidiuresis (NSIAD): a paradigm for activating mutations causing endocrine dysfunction (2006) Pediatr Endocrinol Rev., 1, pp. 66-70. , Dec;4 Suppl
23. Moses, A.M., Scheinman, S.J., Hereditary vasopressin resistance in man and mouse (1993) Ann N Y Acad Sci., 689, pp. 233-249. , Jul 22;
24. Schott III, H.C., Bayly, W.M., Reed, S.M., Brobst, D.F., Nephrogenic diabetes insipidus in sibling colts (1993) J Vet Intern Med., 7 (2), pp. 68-72. , Mar-Apr;
25. Boselt, I., Rompler, H., Hermsdorf, T., Thor, D., Busch, W., Schulz, A., Involvement of the V2 vasopressin receptor in adaptation to limited water supply (2009) PLoS One., 4 (5), pp. e5573
26. Snyder, H.M., Noland, T.D., Breyer, M.D., cAMP-dependent protein kinase mediates hydrosmotic effect of vasopressin in collecting duct (1992) Am J Physiol., 263 (1), pp. C147-53. , Jul
27. Eto, K., Noda, Y., Horikawa, S., Uchida, S., Sasaki, S., Phosphorylation of aquaporin-2 regulates its water permeability (2010) J Biol Chem., 285 (52), pp. 40777-40784. , Dec 24;
28. Christensen, B.M., Zelenina, M., Aperia, A., Nielsen, S., Localization and regulation of PKA-phosphorylated AQP2 in response to V(2)-receptor agonist/antagonist treatment (2000) Am J Physiol Renal Physiol., 278 (1), pp. F29-42. , Jan
29. Kuwahara, M., Fushimi, K., Terada, Y., Bai, L., Marumo, F., Sasaki, S., cAMP-dependent phosphorylation stimulates water permeability of aquaporin-collecting duct water channel protein expressed in Xenopus oocytes (1995) J Biol Chem., 270 (18), pp. 10384-10387. , May 5;
30. Wade, J.B., Stetson, D.L., Lewis, S.A., ADH action: evidence for a membrane shuttle mechanism (1981) Ann N Y Acad Sci., 372, pp. 106-117
31. Yasui, M., Zelenin, S.M., Celsi, G., Aperia, A., Adenylate cyclase-coupled vasopressin receptor activates AQP2 promoter via a dual effect on CRE and AP1 elements (1997) Am J Physiol., 272 (4 PT 2), pp. F443-50. , Apr
32. Deen, P.M., Mouse models for congenital nephrogenic diabetes insipidus: what can we learn from them? (2007) Nephrol Dial Transplant, 22 (4), pp. 1023-1026. , Apr
33. Jaenike, J.R., The influence of vasopressin on the permeability of the mammalian collecting duct to urea (1961) J Clin Invest., 40, pp. 144-151. , Jan;
34. Zhang, C., Sands, J.M., Klein, J.D., Vasopressin rapidly increases phosphorylation of UT-A1 urea transporter in rat IMCDs through PKA (2002) Am J Physiol Renal Physiol., 282 (1), pp. F85-90. , Jan
35. Ecelbarger, C.A., Kim, G.H., Wade, J.B., Knepper, M.A., Regulation of the abundance of renal sodium transporters and channels by vasopressin (2001) Exp Neurol., 171 (2), pp. 227-234. , Oct;
36. Gimenez, I., Forbush, B., Short-term stimulation of the renal Na-K-Cl cotransporter (NKCC2) by vasopressin involves phosphorylation and membrane translocation of the protein (2003) J Biol Chem., 278 (29), pp. 26946-26951. , Jul 18;
37. Manning, M., Lammek, B., Kolodziejczyk, A.M., Seto, J., Sawyer, W.H., Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin (1981) J Med Chem., 24 (6), pp. 701-706. , Jun;
38. Kinter, L.B., Huffman, W.F., Stassen, F.L., Antagonists of the antidiuretic activity of vasopressin (1988) Am J Physiol., 254 (2 PT 2), pp. F165-77. , Feb
39. Hofbauer, K.G., Mah, S.C., Opperman, J.R., Chronic blockade of vasopressin receptors in rats (1986) J Cardiovasc Pharmacol., 8 (SUPPL. 7), pp. S56-60
40. Mah, S.C., Opperman, J.R., Baum, H.P., Hofbauer, K.G., Biologic response to chronic blockade of vasopressin receptors in Sprague-Dawley rats (1988) J Pharmacol Exp Ther., 245 (3), pp. 1021-1027. , Jun;
41. Peri, A., The Use of Vaptans in Clinical Endocrinology (2013) J Clin Endocrinol Metab., , Feb 11
42. Yamamura, Y., Ogawa, H., Yamashita, H., Chihara, T., Miyamoto, H., Nakamura, S., Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist (1992) Br J Pharmacol., 105 (4), pp. 787-791. , Apr;
43. Yamamura, Y., Ogawa, H., Chihara, T., Kondo, K., Onogawa, T., Nakamura, S., OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist (1991) Science., 252 (5005), pp. 572-574. , Apr 26;
44. Ohnishi, A., Orita, Y., Okahara, R., Fujihara, H., Inoue, T., Yamamura, Y., Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men (1993) J Clin Invest., 92 (6), pp. 2653-2659. , Dec;
45. Yamamura, Y., Nakamura, S., Itoh, S., Hirano, T., Onogawa, T., Yamashita, T., OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats (1998) J Pharmacol Exp Ther., 287 (3), pp. 860-867. , Dec;
46. Fujita, N., Ishikawa, S.E., Sasaki, S., Fujisawa, G., Fushimi, K., Marumo, F., Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats (1995) Am J Physiol., 269 (6 PT 2), pp. F926-31. , Dec
47. Xu, D.L., Martin, P.Y., Ohara, M., St John, J., Pattison, T., Meng, X., Upregulation of aquaporin-2 water channel expression in chronic heart failure rat (1997) J Clin Invest., 99 (7), pp. 1500-1505. , Apr 1;
48. Gattone III, V.H., Maser, R.L., Tian, C., Rosenberg, J.M., Branden, M.G., Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease (1999) Dev Genet., 24 (3-4), pp. 309-318
49. Upadhyay, A., Jaber, B.L., Madias, N.E., Incidence and prevalence of hyponatremia (2006) Am J Med., 119 (SUPPL. 1), pp. S30-5. , Jul
50. Verbalis, J.G., Goldsmith, S.R., Greenberg, A., Schrier, R.W., Sterns, R.H., Hyponatremia treatment guidelines 2007: expert panel recommendations (2007) Am J Med., 120 (SUPPL. 1), pp. S1-21. , Nov
51. Hawkins, R.C., Age and gender as risk factors for hyponatremia and hypernatremia (2003) Clin Chim Acta., 337 (1-2), pp. 169-172. , Nov;
52. Palmer, B.F., Gates, J.R., Lader, M., Causes and management of hyponatremia (2003) Ann Pharmacother., 37 (11), pp. 1694-1702. , Nov;
53. Loh, J.A., Verbalis, J.G., Disorders of water and salt metabolism associated with pituitary disease (2008) Endocrinol Metab Clin North Am., 37 (1), pp. 213-234. , Mar;
54. Schwartz, W.B., Bennett, W., Curelop, S., Bartter, F.C., A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone (1957) Am J Med., 23 (4), pp. 529-542. , Oct;
55. Verbalis, J.G., Managing hyponatremia in patients with syndrome of inappropriate antidiuretic hormone secretion (2010) Endocrinol Nutr., 2, pp. 30-40. , May;57 Suppl
56. Smith, D., Moore, K., Tormey, W., Baylis, P.H., Thompson, C.J., Downward resetting of the osmotic threshold for thirst in patients with SIADH (2004) Am J Physiol Endocrinol Metab., 287 (5), pp. E1019-23. , Nov
57. Zietse, R., van der Lubbe, N., Hoorn, E.J., Current and future treatment options in SIADH (2009) NDT Plus., (2 SUPPL 3), pp. iii12-iii9. , Nov
58. Decaux, G., Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by long loop diuretics (1983) Nephron., 35 (2), pp. 82-88
59. Decaux, G., Genette, F., Urea for long-term treatment of syndrome of inappropriate secretion of antidiuretic hormone (1981) Br Med J (Clin Res Ed)., 283 (6299), pp. 1081-1083. , Oct 24;
60. Decaux, G., Unger, J., Brimioulle, S., Mockel, J., Hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. Rapid correction with urea, sodium chloride, and water restriction therapy (1982) JAMA, 247 (4), pp. 471-474. , Jan 22-29;
61. Decaux, G., Brimioulle, S., Genette, F., Mockel, J., Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea (1980) Am J Med., 69 (1), pp. 99-106. , Jul;
62. Schrier, R.W., Gross, P., Gheorghiade, M., Berl, T., Verbalis, J.G., Czerwiec, F.S., Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia (2006) N Engl J Med., 355 (20), pp. 2099-2112. , Nov 16;
63. Velez, J.C., Dopson, S.J., Sanders, D.S., Delay, T.A., Arthur, J.M., Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience (2010) Nephrol Dial Transplant., 25 (5), pp. 1524-1531. , May;
64. Zeltser, D., Rosansky, S., van Rensburg, H., Verbalis, J.G., Smith, N., Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia (2007) Am J Nephrol., 27 (5), pp. 447-457
65. Decaux, G., Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985 (2001) J Lab Clin Med., 138 (1), pp. 18-21. , Jul;
66. Soupart, A., Gross, P., Legros, J.J., Alfoldi, S., Annane, D., Heshmati, H.M., Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist (2006) Clin J Am Soc Nephrol., 1 (6), pp. 1154-1160. , Nov;
67. Colucci, W.S., Braunwald, E., Pathophysiology of heart failure (2005) Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, , 7th ed. Phyladelphia: Elsevier-Saunders
68. Katz, A.M., Konstam, M.A., Heart failure: pathophysiology, molecular biology, and clinical management (2009), 2nd ed. ed. Philadelphia: Lippincott Williams & Wilkins
69. Nielsen, S., Terris, J., Andersen, D., Ecelbarger, C., Frokiaer, J., Jonassen, T., Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct (1997) Proc Natl Acad Sci U S A., 94 (10), pp. 5450-5455. , May 13;
70. Inoue, B.H., dos Santos, L., Pessoa, T.D., Antonio, E.L., Pacheco, B.P., Savignano, F.A., Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure (2011) Am J Physiol Regul Integr Comp Physiol., 302 (1), pp. R166-74
71. Pedersen, R.S., Bentzen, H., Bech, J.N., Nyvad, O., Pedersen, E.B., Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load (2003) Kidney Int., 63 (4), pp. 1417-1425. , Apr;
72. Funayama, H., Nakamura, T., Saito, T., Yoshimura, A., Saito, M., Kawakami, M., Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure (2004) Kidney Int., 66 (4), pp. 1387-1392. , Oct;
73. Martin, P.Y., Abraham, W.T., Lieming, X., Olson, B.R., Oren, R.M., Ohara, M., Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure (1999) J Am Soc Nephrol., 10 (10), pp. 2165-2170. , Oct;
74. Gheorghiade, M., Gottlieb, S.S., Udelson, J.E., Konstam, M.A., Czerwiec, F., Ouyang, J., Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia (2006) Am J Cardiol., 97 (7), pp. 1064-1067. , Apr 1;
75. Berl, T., Quittnat-Pelletier, F., Verbalis, J.G., Schrier, R.W., Bichet, D.G., Ouyang, J., Oral tolvaptan is safe and effective in chronic hyponatremia (2010) J Am Soc Nephrol., 21 (4), pp. 705-712
76. Konstam, M.A., Gheorghiade, M., Burnett Jr., J.C., Grinfeld, L., Maggioni, A.P., Swedberg, K., Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial (2007) JAMA., 297 (12), pp. 1319-1331. , Mar 28;
77. Gheorghiade, M., Orlandi, C., Burnett, J.C., Demets, D., Grinfeld, L., Maggioni, A., Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) (2005) J Card Fail., 11 (4), pp. 260-269. , May;
78. Udelson, J.E., Smith, W.B., Hendrix, G.H., Painchaud, C.A., Ghazzi, M., Thomas, I., Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure (2001) Circulation., 104 (20), pp. 2417-2423. , Nov 13;
79. Goldsmith, S.R., Elkayam, U., Haught, W.H., Barve, A., He, W., Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study (2008) J Card Fail., 14 (8), pp. 641-647. , Oct;
80. Duffin, J.M., Why does cirrhosis belong to Laennec? (1987) CMA.J., 137 (5), pp. 393-396. , Sep 1
81. Anthony, P.P., Ishak, K.G., Nayak, N.C., Poulsen, H.E., Scheuer, P.J., Sobin, L.H., The morphology of cirrhosis: definition, nomenclature, and classification (1977) Bull World Health Organ., 55 (4), pp. 521-540
82. Schuppan, D., Afdhal, N.H., Liver cirrhosis (2008) Lancet., 371 (9615), pp. 838-851. , Mar 8;
83. Gines, P., Schrier, R.W., Renal failure in cirrhosis (2009) N Engl J Med., 361 (13), pp. 1279-1290. , Sep 24;
84. Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D.C., Roudot-Thoraval, F., The burden of liver disease in Europe: a review of available epidemiological data (2013) J Hepatol., 58 (3), pp. 593-608. , Mar;
85. Gines, P., Guevara, M., Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management (2008) Hepatology., 48 (3), pp. 1002-1010. , Sep;
86. Bengus, A., Babiuc, R.D., Hyponatremia-predictor of adverse prognosis in cirrhosis J Med Life., 5 (2), pp. 176-178. , Jun 12
87. McCormick, P.A., Mistry, P., Kaye, G., Burroughs, A.K., McIntyre, N., Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites (1990) Gut., 31 (2), pp. 204-207. , Feb;
88. Cardenas, A., Gines, P., Marotta, P., Czerwiec, F., Oyuang, J., Guevara, M., Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis (2011) J Hepatol., 56 (3), pp. 571-578. , Mar;
89. Cardenas, A., Gines, P., Management of patients with cirrhosis awaiting liver transplantation (2011) Gut., 60 (3), pp. 412-421. , Mar;
90. Gines, P., Wong, F., Watson, H., Milutinovic, S., del Arbol, L.R., Olteanu, D., Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial (2008) Hepatology., 48 (1), pp. 204-213. , Jul;
91. Okita, K., Sakaida, I., Okada, M., Kaneko, A., Chayama, K., Kato, M., A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis (2010) J Gastroenterol., 45 (9), pp. 979-987. , Sep;
92. Nielsen, S., Marples, D., Frokiaer, J., Knepper, M., Agre, P., The aquaporin family of water channels in kidney: an update on physiology and pathophysiology of aquaporin-2 (1996) Kidney Int., 49 (6), pp. 1718-1723. , Jun;
93. Ivarsen, P., Frokiaer, J., Aagaard, N.K., Hansen, E.F., Bendtsen, F., Nielsen, S., Increased urinary excretion of aquaporin 2 in patients with liver cirrhosis (2003) Gut., 52 (8), pp. 1194-1199. , Aug;
94. Guyader, D., Patat, A., Ellis-Grosse, E.J., Orczyk, G.P., Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites (2002) Hepatology., 36 (5), pp. 1197-1205. , Nov;
95. Yu, C., Sharma, N., Saab, S., Hyponatremia: clinical associations, prognosis, and treatment in cirrhosis (2013) Exp Clin Transplant., 11 (1), pp. 3-11. , Feb;
96. Gerbes, A.L., Gulberg, V., Gines, P., Decaux, G., Gross, P., Gandjini, H., Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial (2003) Gastroenterology., 124 (4), pp. 933-939. , Apr;
97. Wong, F., Watson, H., Gerbes, A., Vilstrup, H., Badalamenti, S., Bernardi, M., Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity (2011) Gut., 61 (1), pp. 108-116. , Jan;
98. Fernandez-Varo, G., Ros, J., Cejudo-Martin, P., Cano, C., Arroyo, V., Rivera, F., Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites (2003) J Hepatol., 38 (6), pp. 755-761. , Jun;
99. Dahl, E., Gluud, L.L., Kimer, N., Krag, A., Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia (2012) Aliment Pharmacol Ther., 36 (7), pp. 619-626. , Oct;
100. Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium (1995) Cell., 81 (2), pp. 289-298. , Apr 21;
101. Peters, D.J., Spruit, L., Saris, J.J., Ravine, D., Sandkuijl, L.A., Fossdal, R., Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease (1993) Nat Genet., 5 (4), pp. 359-362. , Dec;
102. Peters, D.J., Sandkuijl, L.A., Genetic heterogeneity of polycystic kidney disease in Europe (1992) Contrib Nephrol., 97, pp. 128-139
103. Collins, A.J., Foley, R.N., Chavers, B., Gilbertson, D., Herzog, C., Johansen, K., 'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States (2012) Am J Kidney Dis., 59 (1), pp. A7+e1-420. , Jan
104. Gabow, P.A., Autosomal dominant polycystic kidney disease (1993) N Engl J Med., 329 (5), pp. 332-342. , Jul 29;
105. Martinez-Maldonado, M., Yium, J.J., Eknoyan, G., Suki, W.N., Adult polycystic kidney disease: studies of the defect in urine concentration (1972) Kidney Int., 2 (2), pp. 107-113. , Aug;
106. Gabow, P.A., Kaehny, W.D., Johnson, A.M., Duley, I.T., Manco-Johnson, M., Lezotte, D.C., The clinical utility of renal concentrating capacity in polycystic kidney disease (1989) Kidney Int., 35 (2), pp. 675-680. , Feb;
107. Seeman, T., Dusek, J., Vondrak, K., Blahova, K., Simkova, E., Kreisinger, J., Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease (2004) Physiol Res., 53 (6), pp. 629-634
108. Michalski, A., Grzeszczak, W., [The effect of hypervolemia on electrolyte level and and level of volume regulating hormones in patients with autosomal dominant polycystic kidney disease] (1996) Pol Arch Med Wewn., 96 (4), pp. 329-343. , Oct;
109. Torres, V.E., Wang, X., Qian, Q., Somlo, S., Harris, P.C., Gattone III, V.H., Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease (2004) Nat Med., 10 (4), pp. 363-364. , Apr;
110. Gattone III, V.H., Wang, X., Harris, P.C., Torres, V.E., Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist (2003) Nat Med., 9 (10), pp. 1323-1326. , Oct;
111. Meijer, E., Bakker, S.J., van der Jagt, E.J., Navis, G., de Jong, P.E., Struck, J., Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease (2011) Clin J Am Soc Nephrol., 6 (2), pp. 361-368. , Feb;
112. Yamaguchi, T., Nagao, S., Wallace, D.P., Belibi, F.A., Cowley, B.D., Pelling, J.C., Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys (2003) Kidney Int., 63 (6), pp. 1983-1994. , Jun;
113. Grantham, J.J., Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach (2003) Kidney Int., 64 (4), pp. 1157-1162. , Oct;
114. Torres, V.E., Cyclic AMP, at the hub of the cystic cycle (2004) Kidney Int., 66 (3), pp. 1283-1285. , Sep;
115. Yasuda, G., Jeffries, W.B., Regulation of cAMP production in initial and terminal inner medullary collecting ducts (1998) Kidney Int., 54 (1), pp. 80-86. , Jul;
116. Lager, D.J., Qian, Q., Bengal, R.J., Ishibashi, M., Torres, V.E., The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease (2001) Kidney Int., 59 (1), pp. 126-136. , Jan;
117. Nagao, S., Watanabe, T., Ogiso, N., Marunouchi, T., Takahashi, H., Genetic mapping of the polycystic kidney gene, pcy, on mouse chromosome 9 (1995) Biochem Genet., 33 (11-12), pp. 401-412. , Dec;
118. Wang, X., Gattone II, V., Harris, P.C., Torres, V.E., Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat (2005) J Am Soc Nephrol., 16 (4), pp. 846-851. , Apr;
119. Wu, G., D'Agati, V., Cai, Y., Markowitz, G., Park, J.H., Reynolds, D.M., Somatic inactivation of Pkd2 results in polycystic kidney disease (1998) Cell., 93 (2), pp. 177-188. , Apr 17;
120. Torres, V.E., Vasopressin antagonists in polycystic kidney disease (2008) Semin Nephrol., 28 (3), pp. 306-317. , May;
121. Higashihara, E., Torres, V.E., Chapman, A.B., Grantham, J.J., Bae, K., Watnick, T.J., Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience (2011) Clin J Am Soc Nephrol., 6 (10), pp. 2499-2507. , Oct;
122. Torres, V.E., Chapman, A.B., Devuyst, O., Gansevoort, R.T., Grantham, J.J., Higashihara, E., Tolvaptan in patients with autosomal dominant polycystic kidney disease (2012) N Engl J Med., 367 (25), pp. 2407-2418. , Dec 20;
123. Torres, V.E., Meijer, E., Bae, K.T., Chapman, A.B., Devuyst, O., Gansevoort, R.T., Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study (2011) Am J Kidney Dis., 57 (5), pp. 692-699. , May;
124. Wuthrich, R.P., Mei, C., Aquaretic treatment in polycystic kidney disease (2012) N Engl J Med., 367 (25), pp. 2440-2442. , Dec 20;
125. Furukawa, M., Umehara, K., Kashiyama, E., Nonclinical pharmacokinetics of a new nonpeptide V2 receptor antagonist, tolvaptan (2011) Cardiovasc Drugs Ther., 25 (SUPPL. 1), pp. S83-9. , Dec
126. Tahara, A., Tomura, Y., Wada, K.I., Kusayama, T., Tsukada, J., Takanashi, M., Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo (1997) J Pharmacol Exp Ther., 282 (1), pp. 301-308. , Jul;
127. Decaux, G., Soupart, A., Vassart, G., Non-peptide arginine-vasopressin antagonists: the vaptans (2008) Lancet., 371 (9624), pp. 1624-1632. , May 10;
128. Veeraveedu, P.T., Palaniyandi, S.S., Yamaguchi, K., Komai, Y., Thandavarayan, R.A., Sukumaran, V., Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents (2010) Drug Discov Today., 15 (19-20), pp. 826-841. , Oct